https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Future Microbiol 2012 Mar;7(3):347-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Future Microbiol 2012 Mar;7(3):347-672012-03-01 00:00:002019-02-15 09:21:32Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-01 / Pancreas 2012 Mar;41(2):195-205
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-01 / Pancreas 2012 Mar;41(2):195-2052012-03-01 00:00:002019-02-15 08:52:32Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-02-29 / Neuroendocrinology 2013;97(1):26-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-02-29 / Neuroendocrinology 2013;97(1):26-342012-02-29 00:00:002019-02-15 09:22:48Virotherapy of neuroendocrine tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-02-15 / Pediatr. Res. 2012 Apr;71(4 Pt 2):500-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-02-15 / Pediatr. Res. 2012 Apr;71(4 Pt 2):500-102012-02-15 00:00:002019-02-15 09:21:31Targeting pediatric cancer stem cells with oncolytic virotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-02-13 / Toxicol. Sci. 2012 May;127(1):139-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-02-13 / Toxicol. Sci. 2012 May;127(1):139-492012-02-13 00:00:002012-02-13 00:00:00Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-132012-01-26 00:00:002019-02-15 08:48:05Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-17 / Cancer 2012 Sep;118(17):4354-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-17 / Cancer 2012 Sep;118(17):4354-622012-01-17 00:00:002023-03-07 13:04:41HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-10 / JOP 2012 Jan;13(1):45-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-10 / JOP 2012 Jan;13(1):45-532012-01-10 00:00:002012-01-10 00:00:00Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-242012-01-03 00:00:002019-02-15 08:46:00Immunotherapy for metastatic colorectal cancer: present status and new options
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Int J Hyperthermia 2012;28(1):9-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Int J Hyperthermia 2012;28(1):9-182012-01-01 00:00:002019-02-15 09:17:17Effector CD8+ T cell IFN-γ production and cytotoxicity are enhanced by mild hyperthermia
